Literature DB >> 29981048

Aptamers that bind to the human complement component receptor hC5aR1 interfere with hC5aR1 interaction to its hC5a ligand.

Penmetcha K R Kumar1.   

Abstract

The complement system plays an important role in inflammation and immunity. In this system, a potent inflammatory ligand is C5a, which initiates its effects by activating its core receptor C5aR1. Thus, compounds that interfere with the C5a-C5aR1 interaction could alleviate some inflammatory conditions. Consequently, several ligands that bind to either C5a or C5aR1 have previously been isolated and evaluated. In the present study, two RNA aptamers, aptamer 1 and aptamer 9, that specifically bind to hC5aR1 with much higher affinity than antibodies were isolated. These two aptamers were tested for their ability to interfere with the cognate ligand of hC5aR1, C5a, using a chemotaxis assay. Both aptamer 1 and 9 interfered with the C5a interaction, suggesting that the aptamers recognized the extracellular domain of hC5aR1 responsible for hC5a ligand binding. Considering the higher affinity of aptamers to the hC5aR1 and their interference with hC5a ligand binding, further study is warranted to explore not only their applications in the diagnosis of inflammatory diseases but also their usefulness in modulating hC5a and hC5aR1 interactions.

Entities:  

Keywords:  Aptamer; C5a; C5aR1; Chemotaxis; Complement system; Inflammation

Mesh:

Substances:

Year:  2018        PMID: 29981048     DOI: 10.1007/s11033-018-4231-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

1.  C5a receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in uticaria pigmentosa by immunohistochemistry.

Authors:  T Werfel; M Oppermann; G Begemann; O Götze; J Zwirner
Journal:  Arch Dermatol Res       Date:  1997-01       Impact factor: 3.017

Review 2.  Aptamers as Valuable Molecular Tools in Neurosciences.

Authors:  Olga Wolter; Günter Mayer
Journal:  J Neurosci       Date:  2017-03-08       Impact factor: 6.167

3.  Characterization of a receptor for C5a anaphylatoxin on human eosinophils.

Authors:  N P Gerard; M K Hodges; J M Drazen; P F Weller; C Gerard
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

Review 4.  Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions.

Authors:  Faith H Brennan; John D Lee; Marc J Ruitenberg; Trent M Woodruff
Journal:  Semin Immunol       Date:  2016-04-03       Impact factor: 11.130

5.  Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site.

Authors:  Adrian Higginbottom; Stuart A Cain; Trent M Woodruff; Lavinia M Proctor; Praveen K Madala; Joel D A Tyndall; Stephen M Taylor; David P Fairlie; Peter N Monk
Journal:  J Biol Chem       Date:  2005-01-20       Impact factor: 5.157

6.  Aptamers that bind to the hemagglutinin of the recent pandemic influenza virus H1N1 and efficiently inhibit agglutination.

Authors:  Subash C B Gopinath; Penmetcha K R Kumar
Journal:  Acta Biomater       Date:  2013-06-20       Impact factor: 8.947

7.  Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry.

Authors:  Subash C B Gopinath; Kyoko Hayashi; Penmetcha K R Kumar
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

8.  Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.

Authors:  Laure Yatime; Christian Maasch; Kai Hoehlig; Sven Klussmann; Gregers R Andersen; Axel Vater
Journal:  Nat Commun       Date:  2015-04-22       Impact factor: 14.919

9.  Aptamers that bind specifically to human KPNA2 (importin-α1) and efficiently interfere with nuclear transport.

Authors:  Noriko Yasuhara; Penmetcha K R Kumar
Journal:  J Biochem       Date:  2016-05-06       Impact factor: 3.387

10.  Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer Can Be an Effective New Strategy to Curb Viral Infection.

Authors:  Tejabhiram Yadavalli; Alex Agelidis; Dinesh Jaishankar; Kyle Mangano; Neel Thakkar; Kumar Penmetcha; Deepak Shukla
Journal:  Mol Ther Nucleic Acids       Date:  2017-10-17
View more
  1 in total

1.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.